New drug aims to starve prostate cancer by blocking testosterone

NCT ID NCT07457164

Not yet recruiting Disease control Sponsor: Antev Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a drug called teverelix DP in 40 men with advanced prostate cancer. The drug works by blocking a hormone that tells the body to make testosterone, which can fuel cancer growth. The goal is to see if a specific dosing schedule can safely lower testosterone to very low levels. Results will help decide if a larger phase 3 study should be done.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teverelix DP (a hormone-blocking drug)
What this could lead to: If successful, this could support a larger Phase 3 study and potentially offer a new treatment option for advanced prostate cancer patients at high cardiovascular risk.
What could go wrong: This is a small, early-phase trial with only 40 participants. It may not show the desired testosterone suppression, and safety issues could arise. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma prostate disorder Urogenital Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PROSTATE CANCER GNRH ANTAGONIST

More trials for these conditions

Other studies related to the condition(s) this trial covers.